Status: Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Participants needed: 124
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Alliance for Clinical Trials in OncologyUpdated: Jul 2, 2026Locations: 780
Eligibility criteria
Histologic documentation: histologically proven intracranial meningioma as docum... [+67]